PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Division of Internal Medicine, University Hospital Basel, Basel, Switzerland.\', \'Laboratory Medicine, Division of Medical Immunology, University Hospital Basel, Basel, Switzerland.\', \'Clinic of Radiology and Nuclear Medicine, University Hospital Basel, Basel, Switzerland.\', \'Pharming Group, Leiden, Netherlands.\', \'Department of Clinical Research and Department of Biomedicine, University Hospital Basel, Basel, Switzerland.\', \'Department of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.3389/fimmu.2020.02072
?:hasPublicationType
?:journal
  • Frontiers in immunology
is ?:pmid of
?:pmid
?:pmid
  • 32922409
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 2.803
?:rankingScore_hIndex
  • 69
is ?:relation_isRelatedTo_publication of
?:title
  • Treatment of COVID-19 With Conestat Alfa, a Regulator of the Complement, Contact Activation and Kallikrein-Kinin System.
?:type
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/32922409>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/32922409>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all